Developing real-world prognostic models for patients with advanced hepatocellular carcinoma: CRAFITY, mALF and beyond

被引：2
|
作者：
Huo, Teh-Ia [1 ,3 ]
Liao, Jia-, I [2 ,4 ]
Ho, Shu-Yein [4 ,5 ]
机构：
[1] Taipei Vet Gen Hosp, Dept Med Res, 201, Sec 2, Shipai Rd, Taipei 11217, Taiwan
[2] Taipei Vet Gen Hosp, Dept Med, Taipei, Taiwan
[3] Natl Yang Ming Chiao Tung Univ, Inst Pharmacol, Taipei, Taiwan
[4] Natl Yang Ming Chiao Tung Univ, Sch Med, Taipei, Taiwan
[5] Min Sheng Gen Hosp, Div Gastroenterol & Hepatol, Taoyuan, Taiwan
来源：
HEPATOLOGY INTERNATIONAL | 2023年 / 17卷 / 02期
关键词：
SCORE;
D O I：
10.1007/s12072-022-10467-9
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：512 / 513
页数：2
相关论文
共 50 条
  • [41] Real-world Treatment Patterns and Reasons for Therapy Selection in Patients with Advanced Hepatocellular Carcinoma in US Oncology Practices
    Klink, Andrew J.
    Marshall, Landon Z.
    Aly, Abdalla
    Seal, Brian
    Healey, Marcus J.
    Feinberg, Bruce
    ONCOLOGIST, 2022, 27 (03): : E265 - E272
  • [42] Real-world experience of atezolizumab plus bevacizumab combination treatment in high risk patients with advanced hepatocellular carcinoma
    Hwang, Sangyoun
    Woo, Hyun Young
    Heo, Jeong
    Kim, Hyung Jun
    Park, Young Joo
    Yi, Kiyoun
    Lee, Yu Rim
    Park, Soo Young
    Jang, Byoung Kuk
    Chung, Woo Jin
    Tak, Won Young
    JOURNAL OF HEPATOLOGY, 2023, 78 : S588 - S588
  • [43] Prognostic outcomes and safety in patients treated with pembrolizumab for advanced urothelial carcinoma: experience in real-world clinical practice
    Tamura, Daichi
    Jinnouchi, Noriaki
    Abe, Masakazu
    Ikarashi, Daiki
    Matsuura, Tomohiko
    Kato, Renpei
    Maekawa, Shigekatsu
    Kato, Yoichiro
    Kanehira, Mitsugu
    Takata, Ryo
    Obara, Wataru
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (05) : 899 - 905
  • [44] Prognostic outcomes and safety in patients treated with pembrolizumab for advanced urothelial carcinoma: experience in real-world clinical practice
    Daichi Tamura
    Noriaki Jinnouchi
    Masakazu Abe
    Daiki Ikarashi
    Tomohiko Matsuura
    Renpei Kato
    Shigekatsu Maekawa
    Yoichiro Kato
    Mitsugu Kanehira
    Ryo Takata
    Wataru Obara
    International Journal of Clinical Oncology, 2020, 25 : 899 - 905
  • [45] Real-world effectiveness of pazopanib in patients with intermediate prognostic risk advanced renal cell carcinoma (PRINCIPAL study)
    Procopio, G.
    Bamias, A.
    Schmidinger, M.
    Hawkins, R.
    Rodriguez Sanchez, A.
    Vazquez, S.
    Srihari, N.
    Kalofonos, H.
    Bono, P.
    Pisal, C.
    Hirschberg, Y.
    Dezzani, L.
    Ahmad, Q.
    Suarez Rodriguez, C.
    Jonasch, E.
    ANNALS OF ONCOLOGY, 2018, 29 : 313 - 313
  • [46] The CRAFITY score emerges as a paramount prognostic indicator in hepatocellular carcinoma patients received Lenvatinib and Pembrolizumab
    Wu, Weijie
    Yang, Zhenyun
    Zou, Hao
    Long, Teng
    Zhou, Zhongguo
    Zhang, Yaojun
    Chen, Minshan
    Hu, Dandan
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [47] Real-world experience of atezolizumab/bevacizumab in hepatocellular carcinoma
    Ha, Yeonjung
    Cheon, Jaekyung
    Hwang, Seong Gyu
    Chon, Hong Jae
    JOURNAL OF HEPATOLOGY, 2021, 75 : S526 - S527
  • [48] Camrelizumab combined with apatinib in the treatment of patients with hepatocellular carcinoma: a real-world assessment
    Chen, Dongbo
    Chen, Xiangxun
    Xu, Lei
    Wang, Yichun
    Zhu, Liyang
    Kang, Mei
    NEOPLASMA, 2023, 70 (04) : 580 - 587
  • [49] Real-world registry of patients with unresectable hepatocellular carcinoma: The OREIOS study.
    Chan, Stephen Lam
    Ryu, Min-Hee
    Waked, Imam
    Shao, Yu Yun
    Tai, Wai Meng David
    Breder, Valeriy
    Alolayan, Ashwaq
    Ganguly, Sandip
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS618 - TPS618
  • [50] Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis
    Hiraoka, Atsushi
    Kumada, Takashi
    Atsukawa, Masanori
    Hirooka, Masashi
    Tsuji, Kunihiko
    Ishikawa, Toru
    Takaguchi, Koichi
    Kariyama, Kazuya
    Itobayashi, Ei
    Tajiri, Kazuto
    Shimada, Noritomo
    Shibata, Hiroshi
    Ochi, Hironori
    Tada, Toshifumi
    Toyoda, Hidenori
    Nouso, Kazuhiro
    Tsutsui, Akemi
    Nagano, Takuya
    Itokawa, Norio
    Hayama, Korenobu
    Imai, Michitaka
    Joko, Kouji
    Koizumi, Yohei
    Hiasa, Yoichi
    Michitaka, Kojiro
    Kudo, Masatoshi
    CANCER MEDICINE, 2019, 8 (08): : 3719 - 3728
12345